Form 4: Cytek Biosciences CEO Wenbin Jiang Reports Changes in Beneficial Ownership

Wenbin Jiang, CEO of Cytek Biosciences, reports transactions involving restricted stock units and common stock, resulting in adjustments to his beneficial ownership.

Summary

• On August 19, 2024, Wenbin Jiang, the President and CEO of Cytek Biosciences, engaged in transactions involving common stock and restricted stock units (RSUs).
• These transactions included the vesting of RSUs and the subsequent acquisition of common stock.
• A portion of the acquired shares was then surrendered to the issuer to cover tax withholding obligations.
• The transactions resulted in a net change in Jiang's beneficial ownership of Cytek Biosciences common stock, with the total amount of shares beneficially owned following the reported transactions being 5,356,896.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing. It doesn't indicate positive or negative sentiment, but rather reports required information about stock transactions.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• Similar filings are common among executives at comparable companies like Agilent Technologies and Danaher Corporation, reflecting standard compensation practices involving stock options and RSUs.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the CEO's stock ownership and transactions.
• It assures stakeholders that insider transactions are being monitored and disclosed in accordance with regulations.

Key Dates